XRTX
XORTX Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · CA
$2.42
+12.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -27.4%
- EBIT
- -15.6%
- EPS
- +44.9%
- Free cash flow
- +40.3%
- Operating cash flow
- -62.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +17.5%
- EBIT
- +17.0%
- Net income
- +15.8%
- EPS
- +48.9%
- Free cash flow
- +24.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026